{"id":"NCT02577016","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)","officialTitle":"A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin Monotherapy in Addition to Diet and Exercise Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-05","primaryCompletion":"2016-11-18","completion":"2016-11-18","firstPosted":"2015-10-15","resultsPosted":"2018-03-07","lastUpdate":"2018-08-31"},"enrollment":141,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sitagliptin","otherNames":["Januvia®, Tesavel®, Xelevia®, Ristaben®, Glactiv®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Ipragliflozin","otherNames":[]}],"arms":[{"label":"Sitagliptin + Ipragliflozin","type":"EXPERIMENTAL"},{"label":"Placebo + Ipragliflozin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study to assess the safety and efficacy of the addition of sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on ipragliflozin, diet, and exercise therapy. The primary hypothesis of the study is that the addition of sitagliptin once daily compared with placebo provides greater reduction in hemoglobin A1C (HbA1c) as assessed by change from baseline (Week 0) to Week 24.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sitagliptin + Ipragliflozin","deltaMin":-0.69,"sd":null},{"arm":"Placebo + Ipragliflozin","deltaMin":0.14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["33565686"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":70},"commonTop":["Nasopharyngitis","Eczema"]}}